Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies
Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA) administered over 24 weeks for treatment of active psoriatic arthritis.
Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to treatment with placebo. Both the INSPIRE-1 and INSPIRE-2 studies achieved the primary endpoint, with a higher proportion of patients in the INSPIRE-1 and INSPIRE-2 studies treated with tildrakizumab achieving ACR20 responses at week 24, compared to those receiving placebo (p < 0.05).
"We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future, said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
8 hours ago
- First Post
Pandemic accelerated brain ageing by 5.5 months, but it may be partly reversible, says UK study
Brain ageing was found to impact cognitive function, with 'brain fog' and difficulty in focussing being common symptoms, only in those who were infected with COVID-19, suggesting that brain ageing alone may not necessarily produce symptoms read more Experiencing the COVID-19 pandemic may have accelerated brain ageing by five and a half months, regardless of one's infection status, according to a new study, which researchers said point to the indirect effects of aspects such as isolation and uncertainty. The researchers, led by those from the University of Nottingham, analysed brain scans of adults in the UK taken before and after the pandemic. They found that changes were most noticeable among the brains of older individuals, men, and people from disadvantaged backgrounds, such as those unemployed and having lower incomes or education. STORY CONTINUES BELOW THIS AD However, brain ageing was found to impact cognitive function, with 'brain fog' and difficulty in focussing being common symptoms, only in those who were infected with COVID-19, suggesting that brain ageing alone may not necessarily produce symptoms. The findings, published in the journal Nature Communications, highlight 'how much the experience of the pandemic itself, everything from isolation to uncertainty, may have affected our brain health,' said lead researcher Ali-Reza Mohammadi-Nejad, research fellow at the university's faculty of medicine and health sciences. 'What surprised me most was that even people who hadn't had Covid showed significant increases in brain ageing rates,' Mohammadi-Nejad added. According to the authors, the pandemic-related brain ageing 'may be at least partially reversible', but being strongly linked with socio-economic deprivation, the policies addressing inequalities are urgently needed, given that existing gaps widened during this time. AI-powered models which were used for predicting brain age were first trained on magnetic resonance image (MRI) brain scans of over 15,000 healthy people from the UK Biobank. The models thus learnt to measure the 'brain age gap' i.e. how much one's brain age differed from their actual age. The models were then employed to analyse two scans of the brains of 996 healthy participants, in 564 people (controls) both the scans were taken before the pandemic, while in the 'Pandemic' group consisting of 432 individuals, one scan was taken before and one after. STORY CONTINUES BELOW THIS AD 'The 'Pandemic' group shows on average (a) 5.5-month higher deviation of brain age gap at the second time point, compared with controls,' the authors wrote. They also found that 'accelerated brain ageing is more pronounced in males and those from deprived socio-demographic backgrounds and these deviations exist regardless of SARS-CoV-2 (virus that causes COVID-19) infection.' Further, cognitive tests taken at the time of both scans revealed that an 'accelerated brain ageing correlates with reduced cognitive performance only in COVID-infected participants.' Senior author Dorothee Auer, professor of neuroimaging at the University of Nottingham, said 'This study reminds us that brain health is shaped not only by illness, but by our everyday environment.' 'The pandemic put a strain on people's lives, especially those already facing disadvantage. We can't yet test whether the changes we saw will reverse, but it's certainly possible, and that's an encouraging thought,' Auer said.
Fibre2Fashion
9 hours ago
- Fibre2Fashion
Godavari Biorefineries gets Chinese patent for cancer molecule
Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. 'Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.' Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world's most urgent health challenges. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Godavari Biorefineries' biotech arm, Sathgen Therapeutics, has secured a Chinese patent for its anti-cancer molecule Hydroxy-1,4-Naphthalenedione. The compound shows strong in vitro efficacy against cancer and cancer stem cells. GBL continues to expand globally, focusing on innovative cancer and antiviral therapies through advanced translational research. ALCHEMPro News Desk (HU)
India Today
9 hours ago
- India Today
Weight-loss drugs work, but here's when the weight starts to return
Weight-loss drugs have become increasingly popular in India and around the world. From pills to new-age injections, pharmaceutical giants are making losing weight easier than ever a new research review has raised a crucial question: what happens after you stop taking them?According to a new study published in BMC Medicine, many patients who lose weight while on these medications tend to regain it once they stop, and it can happen as quickly as 8 weeks after The research looked at data from 11 previously conducted clinical trials involving nearly 2,500 participants. Of these, six studies focused on semaglutide, the active ingredient in popular drugs like Ozempic and these drugs helped participants lose weight during treatment, the benefits faded after the medications were 4 weeks after stopping the drugs, there was no prominent change in weight compared to those not on 8 weeks, participants began regaining weight, an average of 1.5 kg, compared to the control 12 weeks, the regain continued, an average of 1.76 20 weeks, people had regained 2.5 kg on weight regain was most noticeable in patients who had been on GLP-1 receptor agonist drugs, such as semaglutide and tirzepatide, the class of drugs that includes Wegovy and researchers, from Peking University People's Hospital, China, say this rebound effect could happen because once the drugs are stopped, the body's appetite and metabolism tend to return to their original of these medications work by mimicking hormones that regulate hunger and fullness, effects that don't last once the drug is out of the this, the study found that even participants who followed lifestyle changes (like improved diet and exercise) during treatment still experienced weight regain after stopping THIS MEANS FOR LONG-TERM WEIGHT MANAGEMENTCurrently, six drugs are approved for obesity treatment in adults: orlistat, naltrexone-bupropion, semaglutide, liraglutide, tirzepatide and these medicines are often effective for short-term weight loss, they are not a permanent solution by findings support the idea that anti-obesity medications should be seen as part of a broader, long-term strategy, which includes lifestyle changes, behavioural therapy, and even bariatric surgery when and patients alike should focus on building sustainable habits such as nutrition, movement, and stress management, alongside any medical researchers put it, more long-term studies are needed to fully understand how to maintain weight loss after stopping these drugs.- EndsMust Watch
